A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours

Stopped early · Phase 1/Phase 2

Conditions studied: Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma, Bladder Carcinoma, Susceptible FGFR3 Genetic Alterations, FGFR3, FGFR3 Overexpression, FGFR3 Receptor, FGFR3 Protein Overexpression, Ovarian Cancer, Colorectal Cancer, Breast Cancer, Liver Cancer, Lung Cancer, Gastric Cancer

In brief

This first-in-human study evaluates safety, tolerability and distribution of \[225Ac\] FPI-1966, \[111In\]-FPI-1967, and vofatamab in patients with FGFR3-expressing solid tumors.

Key facts

Study ID

NCT05363605

Run by

Fusion Pharmaceuticals Inc.

People needed

6

Starts

2022-04-20

Expected to finish

2023-09-08

Last updated by the study team

2023-12-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• City of Hope — Duarte, California, United States
• University of California, San Francisco — San Francisco, California, United States
• University of Iowa Hospitals and Clinics — Iowa City, Iowa, United States
• Memorial Sloan Kettering Cancer Center — New York, New York, United States
• GC Murdoch — Murdoch, Western Australia, Australia
• St Vincent's Hospital — Melbourne, Australia

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.